Beam Therapeutics (BEAM) Competitors

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Does the media refer more to BEAM or CRSP?

In the previous week, CRISPR Therapeutics had 6 more articles in the media than Beam Therapeutics. MarketBeat recorded 26 mentions for CRISPR Therapeutics and 20 mentions for Beam Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.72 beat Beam Therapeutics' score of 0.34 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, BEAM or CRSP?

Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Is BEAM or CRSP more profitable?

Beam Therapeutics has a net margin of -661.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-661.31%	-43.15%	-31.06%
CRISPR Therapeutics	-1,229.43%	-20.05%	-17.09%

Which has better earnings & valuation, BEAM or CRSP?

CRISPR Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$63.52M	28.38	-$376.74M	-$4.50	-3.96
CRISPR Therapeutics	$37.31M	145.60	-$366.25M	-$5.43	-11.00

Do institutionals & insiders hold more shares of BEAM or CRSP?

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts prefer BEAM or CRSP?

Beam Therapeutics currently has a consensus target price of $48.45, suggesting a potential upside of 171.91%. CRISPR Therapeutics has a consensus target price of $71.60, suggesting a potential upside of 19.87%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.07
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Beam Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.